Development and characterization of suppository formulation for rectal delivery of clarithromycin
Letters in Drug Design & Discovery · 2025-08 · 22 (8) · 100110
DOI: 10.1016/j.lddd.2025.100110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Letters in Drug Design & Discovery, 2025-08. Verfasst von Sharoon Mirza und 7 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Clarithromycin (CLR), a broad-spectrum antibiotic, is widely used to treat genitourinary infections caused by Gram positive bacteria via conventional drug delivery approaches, such as tablets. However, bitter taste, nausea and first pass hepatic effects hamper its usage. Moreover, CLR exhibits poor flow property making it difficult to formulate into tablet dosage form. The current study aimed to formulate CLR suppositories to address limitations associated with its oral administration. CLR suppositories were prepared using a molding method and characterized by different analytical techniques to assess the bioavailability of the drug using in vitro and in vivo models. Fourier Transform Infrared analysis indicated no significant chemical interaction between CLR and the suppository base. X-ray diffraction results showed a transformation from crystalline to amorphous form with effective drug loading. Differential scanning calorimetry analysis confirmed the thermal stability of CLR in suppository dosage form. In vitro drug release profile showed that drug release was sustained for 3 hrs. In vivo studies demonstrated significantly greater inhibition of bacterial growth after administration of suppositories (50 ± 5 mm) as compared to oral tablets (20 ± 3 mm). In vivo evaluation was also performed to investigate the antimicrobial efficacy against genitourinary bacterial infections. These findings highlight the potential of CLR suppositories to improve stability and bioavailability compared to oral tablets. However, further clinical studies are needed to confirm its clinical efficacy and safety in humans.
Zitieren
APA
Mirza, S., Baseer, A., Rahim, A., Rehman, M., Badshah, M., Younatan, Y., Ullah, K. H., & Iqbal, H. (2025). Development and characterization of suppository formulation for rectal delivery of clarithromycin. Letters in Drug Design & Discovery, 22(8), 100110. https://doi.org/10.1016/j.lddd.2025.100110
Vancouver
Mirza S, Baseer A, Rahim A, Rehman M, Badshah M, Younatan Y, et al. Development and characterization of suppository formulation for rectal delivery of clarithromycin. Letters in Drug Design & Discovery. 2025;22(8):100110. doi:10.1016/j.lddd.2025.100110
BibTeX
@article{Mirza2025,
author = {Mirza, Sharoon and Baseer, Abdul and Rahim, Abdur and Rehman, Mehreen and Badshah, Munair and Younatan, Yamema and Ullah, Kamran Hidayat and Iqbal, Hamid},
title = {Development and characterization of suppository formulation for rectal delivery of clarithromycin},
journal = {Letters in Drug Design & Discovery},
year = {2025},
volume = {22},
number = {8},
pages = {100110},
doi = {10.1016/j.lddd.2025.100110}
}
EUVIMED